Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6100508 | Journal of Crohn's and Colitis | 2012 | 4 Pages |
Abstract
To the best of our knowledge, this is the second case report of HSP complicating adalimumab therapy. Although adalimumab is theoretically less related to immune-mediated reactions, clinicians must be aware that adverse side effects may still occur. This is the first case that shows that infliximab can be safely used in patients with adalimumab related HSP. We discuss the literature and potential causal mechanisms and propose possible approaches to its management.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Inês Marques, Ana Lagos, Jorge Reis, António Pinto, Beatriz Neves,